Antiviral Drugs - Italy

Italy

Italy is projected to see a significant revenue growth in the Antiviral Drugs market.
By 2024, the projected revenue is expected to reach €0.64bn.
This growth is anticipated to continue with an annual growth rate of 1.22% from 2024 to 2029.
Consequently, the market volume in Italy is estimated to reach €0.68bn by 2029.
In a global comparison, it is noteworthy that United States is expected to generate the highest revenue in the Antiviral Drugs market, reaching €28,420.00m in 2024.
Italy is experiencing a surge in demand for antiviral drugs as the country battles against the ongoing COVID-19 pandemic.

Key regions: Brazil, India, Australia, United States, United Kingdom

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Antiviral Drugs market in Italy has been experiencing significant development in recent years.

Customer preferences: Italian customers have been increasingly prioritizing health and wellness, leading to a growing demand for antiviral drugs. Additionally, the aging population in Italy has also contributed to the rising demand for antiviral drugs as older individuals are more susceptible to viral infections.

Trends in the market: One of the major trends in the Antiviral Drugs market in Italy is the increasing focus on research and development of new drugs. Italian pharmaceutical companies have been investing heavily in R&D to develop new antiviral drugs that are more effective and have fewer side effects. Another trend is the increasing use of combination therapy, where multiple antiviral drugs are used together to treat viral infections.

Local special circumstances: The COVID-19 pandemic has had a significant impact on the Antiviral Drugs market in Italy. The pandemic has led to a surge in demand for antiviral drugs, particularly those used to treat COVID-19. Italian pharmaceutical companies have been working to develop new antiviral drugs specifically for COVID-19, and the government has been investing in research to support this effort.

Underlying macroeconomic factors: Italy's healthcare system is publicly funded, which means that the government plays a significant role in regulating the Antiviral Drugs market. The government has been working to increase access to antiviral drugs for all citizens, particularly those with lower incomes. Additionally, the Italian pharmaceutical industry is highly regulated, which has led to a focus on quality and safety in the development of new drugs. Finally, Italy's membership in the European Union has led to increased competition in the Antiviral Drugs market as companies from other EU countries are allowed to sell their products in Italy.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.